Coherus Oncology, Inc. (CHRS) Gross margin 2019–2025
Coherus Oncology, Inc. (CHRS) gross margin by fiscal year — reported gross profit divided by reported revenue.
67.2%FY2025 · since FY2019: 95.2% → 67.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 67.2% | +0.3 pp |
| FY2024 | 66.9% | +28.7 pp |
| FY2023 | 38.2% | -28.6 pp |
| FY2022 | 66.8% | -15.6 pp |
| FY2021 | 82.4% | -9.7 pp |
| FY2020 | 92.1% | -3.1 pp |
| FY2019 | 95.2% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice